Bhasker R. Mehta, M.D. – FDA 483, Jun 2, 2026

An FDA inspection of Bhasker R. Mehta, M.D., a clinical investigator in Arlington, TX, revealed significant deviations from the investigational plan. The firm failed to ensure subjects met eligibility criteria prior to randomization and improperly administered investigational product, leading to both underdosing and overdosing of study participants. These findings indicate serious non-compliance with clinical trial protocols.